Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma

被引：0

作者：

Cejalvo, Maria J. ^{[1
]}

de la Rubia, Javier ^{[1
,2
]}

机构：

[1] Univ Hosp Doctor Peset, Hematol Serv, Valencia 46017, Spain

[2] Univ Catolica Valencia San Vicente Martir, Valencia, Spain

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 11期

关键词：

front-line therapy; immunomodulatory drugs; lenalidomide; multiple myeloma; STEM-CELL TRANSPLANTATION; IMMUNOMODULATORY THALIDOMIDE ANALOG; LOW-DOSE DEXAMETHASONE; PHASE-I; PLUS DEXAMETHASONE; COMBINATION THERAPY; RENAL IMPAIRMENT; DRUG-RESISTANCE; INITIAL THERAPY; BORTEZOMIB;

D O I：

10.2217/fon.15.51

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The availability of novel drugs with different and innovative mechanisms of action such as proteasome inhibitors such as bortezomib and immunomdulatory agents as thalidomide and lenalidomide have changed the landscape of the treatment of patients with newly diagnosed multiple myeloma, allowing the development of several new therapeutic regimens both for transplant-eligible and -ineligible patients. Among these new agents, lenalidomide has become one of the most commonly used in these patients. In this article, we review the current state-of-the-art of different induction and maintenance lenalidomide-containing regimens administered in transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma. We also discuss the safety profile and potential long-term side effects of this drug and analyze its utility in certain subgroups of patients like those with high-risk disease or different degrees of renal impairment.

引用

页码：1643 / 1658

页数：16

共 80 条

[1]

Akiyama M, 2002, CANCER RES, V62, P3876

[2] Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines [J].

Anderson, Kenneth C. ;

Alsina, Melissa ;

Bensinger, William ;

Biermann, J. Sybil ;

Cohen, Adam D. ;

Devine, Steven ;

Djulbegovic, Benjamin ;

Faber, Edward A., Jr. ;

Gasparetto, Cristina ;

Hernandez-Illizaliturri, Francisco ;

Huff, Carol Ann ;

Kassim, Adetola ;

Krishnan, Amrita Y. ;

Liedtke, Michael ;

Meredith, Ruby ;

Raje, Noopur ;

Schriber, Jeffrey ;

Singhal, Seema ;

Somlo, George ;

Stockerl-Goldstein, Keith ;

Treon, Steven P. ;

Weber, Donna ;

Yahalom, Joachim ;

Yunus, Furhan ;

Shead, Dorothy A. ;

Kumar, Rashmi .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (01) :11-17

[3] Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Marit, Gerald ;

Caillot, Denis ;

Moreau, Philippe ;

Facon, Thierry ;

Stoppa, Anne Marie ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Garderet, Laurent ;

Decaux, Olivier ;

Leyvraz, Serge ;

Vekemans, Marie-Christiane ;

Voillat, Laurent ;

Michallet, Mauricette ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Roussel, Murielle ;

Leleu, Xavier ;

Mathiot, Claire ;

Payen, Catherine ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791

[4] Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents [J].

Bartlett, JB ;

Dredge, K ;

Dalgleish, AG .

NATURE REVIEWS CANCER, 2004, 4 (04) :314-322

[5] Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma [J].

Benboubker, Lotfi ;

Dimopoulos, Meletios A. ;

Dispenzieri, Angela ;

Catalano, John ;

Belch, Andrew R. ;

Cavo, Michele ;

Pinto, Antonello ;

Weisel, Katja ;

Ludwig, Heinz ;

Bahlis, Nizar ;

Banos, Anne ;

Tiab, Mourad ;

Delforge, Michel ;

Cavenagh, Jamie ;

Geraldes, Catarina ;

Lee, Je-Jung ;

Chen, Christine ;

Oriol, Albert ;

de la Rubia, Javier ;

Qiu, Lugui ;

White, Darrell J. ;

Binder, Daniel ;

Anderson, Kenneth ;

Fermand, Jean-Paul ;

Moreau, Philippe ;

Attal, Michel ;

Knight, Robert ;

Chen, Guang ;

Van Oostendorp, Jason ;

Jacques, Christian ;

Ervin-Haynes, Annette ;

Avet-Loiseau, Herve ;

Hulin, Cyrille ;

Facon, Thierry .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) :906-917

[6] Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective [J].

Bwire, Robert ;

Freeman, John ;

Houn, Florence .

EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) :3-8

[7] No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers [J].

Chen, Nianhang ;

Weiss, Daniel ;

Reyes, Josephine ;

Liu, Liangang ;

Kasserra, Claudia ;

Wang, Xiaomin ;

Zhou, Simon ;

Kumar, Gondi ;

Weiss, Lilia ;

Palmisano, Maria .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) :1031-1039

[8] Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects [J].

Chen, Nianhang ;

Wen, Lian ;

Lau, Henry ;

Surapaneni, Sekhar ;

Kumar, Gondi .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) :789-797

[9] Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses [J].

Chen, Nianhang ;

Lau, Henry ;

Choudhury, Somesh ;

Wang, Xiaomin ;

Assaf, Mahmoud ;

Laskin, Oscar L. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (07) :767-774

[10] Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis [J].

Chen, Nionhang ;

Lau, Henry ;

Kon, Linghui ;

Kumar, Gondi ;

Zeldis, Jerome B. ;

Knight, Robert ;

Laskin, Oscar L. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (12) :1466-1475

← 1 2 3 4 5 6 7 8 →